US › Healthcare

Tenaya Therapeutics Inc (TNYA)

US · Healthcare · Biotechnology

$0.74+1.73%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$225,000
Net profit
$-19.3M
Profit YoY
+28.3%
EPS
$-0.09
EPS estimate
$-0.09
Net margin
-8,565.3%

EPS came in at -0.09 against a street estimate of -0.09 — a beat of 0.0%.

Key statistics

Market cap
$160.6M
Forward P/E
0.0
P/B
1.53
Book value
$0.49
EPS (TTM)
$-0.45
52-week high
$2.35
52-week low
$0.53
50-day MA
$0.78
200-day MA
$0.90
Beta
2.84

Analyst view

Analysts rate Tenaya Therapeutics Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $3.20.

Shareholding

Insiders
0.47%
Institutions
48.34%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC3.91%
Millennium Management LLC2.51%
Empery Asset Management, LP1.98%
Citadel Advisors Llc1.94%
Kalehua Capital Management LLC1.84%
Renaissance Technologies Corp1.71%
BlackRock Inc1.71%
Marshall Wace Asset Management Ltd1.25%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Tenaya Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.